Provention Bio, Inc.: Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US

Companies collaborating to expand access to TZIELD (teplizumab-mzwv), the first approved disease-modifying therapy for type 1 diabetes RED BANK, N.J., Feb. 13, 2023 /PRNewswire/ -- Provention Bio

Related Keywords

United States ,Kaelan Hollon ,Thierry Chauche ,Jason Hoitt ,Olivier Bogillot ,Provention Bio ,Provention Bio Inc ,Twitter ,Provention Bio Patient Assistance Program ,Nasdaq ,Exchange Commission ,Trademark Office ,Prnewswire Provention Bio Inc ,Sanofi Us Co ,Trademarks Of Provention Bio Inc ,Provention Bio Copay Program ,Co Promotion Agreement ,Securities Purchase Agreement ,Chief Commercial Officer ,Purchase Agreement ,Patient Assistance Program ,Safety Information ,Release Syndrome ,Hypersensitivity Reactions ,United States Patent ,Chief Financial ,Marcel Torney ,Provention ,Nnounces ,Completion ,Billion ,Equity ,Investment ,Rom ,Sanofi ,